OR WAIT 15 SECS
Novotec has signed an MOU with the Korea Drug Development Fund to promote the development of the Korean biotechnology sector in the Asia Pacific region.
Novotech, Australia’s largest clinical CRO with offices throughout Asia, has signed an MOU with the Korea Drug Development Fund (KDDF) to promote the development of the Korean biotechnology sector in the Asia Pacific region. Korea is one of the most sophisticated biotechnology markets in Asia.
Novotech made the announcement at the Drug Industry Association (DIA) conference today in San Diego (Novotech booth # 1236).
KDDF’s CEO, Dr. Dongho Lee, said, “We are delighted to have built a stronger relationship with Novotech. We were particularly attracted to Novotech’s proven track record and leading position in Australia and New Zealand and access to diverse patient populations across Asia Pacific. Novotech’s reach also allows trials to be conducted across a range of geographies and seasons. Together with Novotech, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation
The MOU was signed by the Novotech Asia COO, Dr.John Mollerand Dr. Lee in the presence of Mr Brett Cooper, the Australian Senior Trade Commissioner.
Dr. Moller was appointed to the Novotech COO Asia role, based in Singapore, in January. He was previously Managing Director at Virtus Health one of the largest integrated fertility groups in the world, and was a strategy consultant with the Boston Consulting Group.
Dr. Moller commended the Australian Trade Commission in Korea for their support of the alliance and assisting with introductions and high-level meetings.
With a budget of US$1 billion, including private matching funds, the Government-backed KDDF is a uniquely positioned to accelerate drug development in Korea.
The MOU with Novotech is part of the KDDF’s vision to transform Korea into a global leader for new drug development .
Novotech is an internationally recognized full service CRO known for its experience across Australia, New Zealand, Asia and South Africa, representing emerging markets with a population base of over 3 billion people.
As a leading regional CRO, Novotech has been actively involved in hundreds of drug development programs for US and EU registration over the past 18 years.
At DIA this week Novotech CEO Alek Safarian said“Korea is rapidly becoming a hub for clinical trials in Asia.The country is a priority market for the company, with its population of 49 million people, first world infrastructure and highly skilled medical and scientific staff. In fact, Novotech’s Korean office in Seoul, established in 2007, was our first in the Asia region.”